treatment-resistant depression
Depression that has not responded to standard treatments; a target indication for psychedelic therapy trials.
As defined in 82 | Robin Carhart-Harris on Psychedelics and the Brain
Where it comes up · 6
- Lex Fridman Podcast #502 - Psychiatry, Insane Asylums, Mental Illness, ECT, Lobotomies, Freud & Jung4 claims
- How Psilocybin Can Rewire Our Brain, Its Therapeutic Benefits & Its Risks2 claims
- 306 - Psychedelics Mortality1 claim
- 177 - Psychedelic Science1 claim
- 127 - Freedom From The Known1 claim
- 82 | Robin Carhart-Harris on Psychedelics and the Brain1 claim
Most important claims · 10 of 10Search all claims for “treatment-resistant depression” →
- Rather than acting as a 'magic bullet' for a single diagnosis, psychedelic therapy shows signal across many disorders (depression, treatment-resistant depression, anxiety, end-of-life distress, addictions, eating disorders, chronic pain, OCD) because these disorders share an underlying structure of cognitive and behavioral 'ruts'; psychedelics flatten the depressed/addicted landscape so the person can explore and move more freely.82 | Robin Carhart-Harris on Psychedelics and the Brain
- Both antipsychotics and antidepressants are at best partially effective and fail for a significant fraction of patients, and psychiatrists cannot know in advance who will respond well, badly, or be balanced between benefit and side effects.Lex Fridman Podcast #502 - Psychiatry, Insane Asylums, Mental Illness, ECT, Lobotomies, Freud & Jung
- A recent Lancet study suggested that with depressed patients, 40 percent or more do not respond to drugs while experiencing risk, a group that gets some benefit with side effects in the middle, and the doctor cannot know in advance which group a patient will fall into.Lex Fridman Podcast #502 - Psychiatry, Insane Asylums, Mental Illness, ECT, Lobotomies, Freud & Jung
- Electroconvulsive therapy appears to work for some severe, suicidal, or treatment-resistant depression, with recent trial evidence, but there is no known mechanism for why it works, making it a purely empirical treatment that alarms people.Lex Fridman Podcast #502 - Psychiatry, Insane Asylums, Mental Illness, ECT, Lobotomies, Freud & Jung
- Electroconvulsive therapy, originally premised on an antagonism between epilepsy and schizophrenia that is false, turned out not useful for schizophrenia but seems to work for severe and suicidal depression, though its effects are often temporary and require maintenance treatment.Lex Fridman Podcast #502 - Psychiatry, Insane Asylums, Mental Illness, ECT, Lobotomies, Freud & Jung
- A 2022 New England Journal of Medicine study (No Surprise: Single Dose Psilocybin for Treatment-Resistant Major Depression) found that a single 25-milligram dose of synthetic psilocybin provided significantly greater relief from treatment-resistant depression at week 3 compared to 10-milligram or 1-milligram placebo doses, with relief remaining stable through week 12.How Psilocybin Can Rewire Our Brain, Its Therapeutic Benefits & Its Risks
- The strongest evidence for psilocybin's therapeutic use is for cancer-related depression, cancer-related anxiety, and treatment-resistant depression; there is moderate evidence for alcohol use disorder, dependence, and tobacco addiction; and weaker evidence for obsessive compulsive disorder, cluster headaches, migraines, and demoralization due to AIDS diagnosis.How Psilocybin Can Rewire Our Brain, Its Therapeutic Benefits & Its Risks
- Two entities are running FDA-approved phase 2b multi-site trials of psilocybin for major depressive disorder or treatment-resistant depression, with promising early results, and approval could be forthcoming in roughly five to seven years or possibly sooner, depending on how clean the trials are and what auxiliary studies the FDA requires.177 - Psychedelic Science
- MDMA for PTSD treatment will very likely be the first psychedelic compound to cross the FDA approval threshold, possibly within two to four years, while psilocybin for depression is moving more slowly at an estimated three to five years.306 - Psychedelics Mortality
- The expansion of psychedelic research into depression came from the FDA itself: when Hopkins and NYU researchers sought approval for a phase 3 study of anxiety and depression in cancer patients, FDA regulators noted a strong signal for depression generally and, given the enormous unmet need and limited tools, encouraged studying depression in a larger population—major depression in America and treatment-resistant depression in Europe.127 - Freedom From The Known